Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancer.

Literature DB >> 27308613

RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancer.

Abstract

ALK (anaplastic lymphoma kinase) inhibitors are approved in for ALK gene rearrangement positive (ALK+) lung cancer, but resistance remains a challenge. We discovered that RAS-RAF-MEK-ERK signaling controls the ALK inhibitor response in ALK+ lung cancer and is critical for ALK inhibitor resistance. Upfront ALK-MEK inhibitor polytherapy may enhance response and forestall resistance.

Entities: Disease Gene

Keywords: ALK; MEK; RAS; lung cancer; resistance; targeted therapy

Year: 2015 PMID： 27308613 PMCID： PMC4905399 DOI： 10.1080/23723556.2015.1091061

Source DB: PubMed Journal: Mol Cell Oncol ISSN： 2372-3556

7 in total

1. Lessons learned from the development of kinase inhibitors.

Authors: Charles L Sawyers
Journal: Clin Adv Hematol Oncol Date: 2009-09

2. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

Authors: Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean Jacques Grob; Vanna Chiarion Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymyr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Michelle Casey; Daniele Ouellet; Anne-Marie Martin; Ngocdiep Le; Kiran Patel; Keith Flaherty
Journal: N Engl J Med Date: 2014-09-29 Impact factor: 91.245

3. Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors: Alice T Shaw; Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Juergen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Yvonne Y Lau; Meredith Goldwasser; Anthony L Boral; Jeffrey A Engelman
Journal: N Engl J Med Date: 2014-03-27 Impact factor: 91.245

4. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

Authors: Gorjan Hrustanovic; Victor Olivas; Evangelos Pazarentzos; Asmin Tulpule; Saurabh Asthana; Collin M Blakely; Ross A Okimoto; Luping Lin; Dana S Neel; Amit Sabnis; Jennifer Flanagan; Elton Chan; Marileila Varella-Garcia; Dara L Aisner; Aria Vaishnavi; Sai-Hong I Ou; Eric A Collisson; Eiki Ichihara; Philip C Mack; Christine M Lovly; Niki Karachaliou; Rafael Rosell; Jonathan W Riess; Robert C Doebele; Trever G Bivona
Journal: Nat Med Date: 2015-08-24 Impact factor: 53.440

5. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors: Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal: N Engl J Med Date: 2013-06-01 Impact factor: 91.245

Review 6. Circumventing cancer drug resistance in the era of personalized medicine.

Authors: Levi A Garraway; Pasi A Jänne
Journal: Cancer Discov Date: 2012-02-28 Impact factor: 39.397

7. Comprehensive molecular profiling of lung adenocarcinoma.

Authors:
Journal: Nature Date: 2014-07-09 Impact factor: 49.962

7 in total

4 in total

1. LncRNA NEAT1/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf-1 and modulating the Ras-MAPK pathway.

Authors: Fei Liu; Yong Tai; Jiqing Ma
Journal: Cancer Biol Ther Date: 2018-04-09 Impact factor: 4.742